Compare 10X Genomics Inc (TXG) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Under Armour Inc Class A — how do they compare? 10X Genomics Inc trades at $67.62 (market cap $8.55B), while Under Armour Inc Class A trades at $4.94 (market cap $2.15B). The key difference: 10X Genomics Inc is far larger — about 4× Under Armour Inc Class A's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| TXG | UAA | |
|---|---|---|
Market Cap | $8.55B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $67.29 | $8.14 |
52-Week Low | $11.34 | $4.17 |
Enterprise Value | $8.08B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Under Armour (UAA) trades at $5.06, down 3.62% amid bearish technical signals and negative cash flow. The company reported Q2 2026 EPS of $0.05, beating expectations, but faces revenue declines and a net loss of $201 million in 2025. Analyst consensus is mixed with 27% buy ratings and a $6.67 price target, while technical indicators show resistance at $5 with RSI neutral but ADX signaling strong bearish momentum.
UAA's outlook is challenged by weakening revenue and negative profitability, though cost controls and international growth offer some support. Investment opportunity exists if margin improvements translate to sustained earnings, but risks include persistent North America softness and high debt levels. The stock trades near analyst low targets, suggesting limited upside without operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
